As a co-founder of Crescent Capital in Sawtelle, Attanasio has overseen the private equity firm Crescent Capital grow to close to $50 billion in assets. A big initiative for the firm this year is the ...

and stock or stock options from TORL Biotherapeutics. ER reports an honorarium for a guest lecture in June, 2019, from the University of Nebraska. DS reports support from Roche-Genentech and Sanofi; ...

Torl Biotherapeutics, 1200 Pharma, Takeda, Aptose Biosciences, and Aptose Biosciences. ZL holds a consulting or advisory role with AstraZeneca and Bristol Myers Squibb. SC served as a speaker and ...

Arcutis Biotherapeutics ( (ARQT)) has provided an announcement. On April 10, 2025, Arcutis Biotherapeutics announced the appointment of Latha Vairavan as the new Chief Financial Officer ...

DelveInsight’s, “Liver Cancer Pipeline Insight” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Liver Cancer pipeline landscape. It covers the Liver ...

TORL-4500 is under clinical development by TORL Biotherapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success ...

TORL BioTherapeutics LLC, a clinical stage biotechnology company discovering and developing new antibody-based immunotherapies to improve and extend the lives of patients with cancer worldwide, has ...

Both will report to chief production officer Graham Johnson. TORL BioTherapeutics hired Aran Maree, MD as chief medical officer. Luckie Health promoted John Petersen to GM. Axsome Therapeutics ...

You have permission to edit this article. Edit Close Activate Subscribe My Account Logout Login/Register ...

2024 /PRNewswire/ -- TORL BioTherapeutics, LLC (TORL), a clinical stage biotechnology company discovering and developing new antibody-based immunotherapies to improve and extend the lives of ...